Biotech | November 13, 2021
Moderna presents data from Phase 1 study of mRNA Triplet programme
The interim data combines three mRNAs into one therapy injected directly into the tumour
The interim data combines three mRNAs into one therapy injected directly into the tumour
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
The collaboration will support Canada with direct access to rapid pandemic response capabilities
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
Subscribe To Our Newsletter & Stay Updated
